Kornimate/medical-research-clean huggingface dataset:
dexcom g6 observational study

Conditions: Diabetes

Summary: this is an exploratory prospective study primary aiming to evaluate differences between point-of-care (poc) testing (standard of care) and dexcom g6 cgm (continues glucose monitoring sensor system) in 1) glycemic control measured by mean daily blood glucose and 2) identifying hypoglycemic and hyperglycemic events - in patients with type 1 and type 2 diabetes treated with basal bolus insulin regimen.

several studies have shown that the use of a device that can measure blood glucose levels every 5 minutes is more effective in identifying low blood glucose (hypoglycemia) and high blood glucose (hyperglycemia) when compared to regular measurements with fingersticks \[point of care (poc)\]. this is an exploratory prospective study primary aiming to evaluate differences between point-of-care (poc) testing (standard of care) and dexcom g6 cgm (continues glucose monitoring sensor system) in 1) glycemic control measured by mean daily blood glucose and 2) identifying hypoglycemic and hyperglycemic events - in patients with type 1 and type 2 diabetes treated with basal bolus insulin regimen.

Eligibility criteria:
inclusion criteria: 1. \> 18 years admitted to a general medicine or surgical service. 2. known history of t1d or t2d receiving insulin therapy 3. subjects must have a randomization bg between 140 mg and 400 mg/dl without laboratory evidence of diabetic ketoacidosis (bicarbonate \< 18 meq/l, ph \< 7.30, or positive serum or urinary ketones). 4. patients with expected hospital length-of-stay of 3 or more days exclusion criteria: 1. patients with acute illness admitted to the icu or expected to require admission to the icu. 2. patients expected to require mri procedures during hospitalization. 3. mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. 4. female subjects who are pregnant or breast-feeding at time of enrollment into the study.

Keywords: glucose monitoring poc bg dexcomg6 cgm
specific lp(a) apheresis for regression of coronary and carotid atherosclerosis

Conditions: Atherosclerosis; Coronary Disease; Carotid Artery Diseases

Summary: to evaluate whether specific lipoprotein(a) apheresis on the top of optimal medical therapy could affect atherosclerotic disease burden in coronary and carotid arteries of coronary heart disease patients with elevated lp(a) levels.

following the hypothesis that if lp(a) excess has a pathogenic role in atherogenesis, then specific elimination of circulating lp(a) should affect plaque growth and stability, we evaluated the efficacy of lp(a) apheresis on changes in coronary plaque volume and composition and carotid intima-media thickness in patients with chd on the background of optimal medical treatment.

Eligibility criteria:
inclusion criteria: * stable coronary heart disease (chd) requiring a clinically indicated coronary angiography. * lp(a) ≥50 mg/dl * ldl-c \<2.6 mmol/l (100 mg/dl) * signed written informed consent form to participate in the study exclusion criteria: * history of acute coronary syndrome or surgical intervention within prior 3 months to inclusion * chronic infectious and inflammatory diseases * familial hypercholesterolemia * tg ≥4.5 mmol/l (400 mg/dl) * active liver disease (alt or ast \>3 upper limit of normal (uln), or total bilirubin \>1.5 uln); * ck ≥3 uln; * thyroid dysfunction; * renal dysfunction (creatinine clearance (cockcroft-gault equation) ≤30 ml/min); * uncontrolled diabetes (hba1c ≥7.0%); * coagulopathies; * lipid-lowering drugs, except statins for the last month * known statin or immunoadsorption intolerance

Keywords: lipoprotein(a); lp(a) immunoadsorption; apheresis; coronary atherosclerosis; carotid atherosclerosis; intima-media thickness; regression; quantitative coronary angiography; intravascular ultrasound; virtual histology; plaque; atorvastatin;
a study to investigate effects of omega-3 carboxylic acids and dapagliflozin on liver fat content in diabetic patients

Conditions: T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)

Summary: this study is a double-blind randomized, placebo-controlled, parallel-group, 12 week study performed in up to 5 centres in sweden to assess the effect of omega-3 carboxylic acids and dapagliflozin on liver fat in patients with type 2 diabetes with fatty liver (\>5.5% as measured with magnetic resonance imaging (mri))


Eligibility criteria:
inclusion criteria: provision of informed consent prior to any study specific procedures; men or women ≥40 years and ≤75 years with suitable veins for cannulation or repeated venepuncture; have liver fat content as assessed by mri \>5.5%; diagnosis of type 2 diabetes since at least 6 months in accordance with who criteria. exclusion criteria: any condition when mri is contraindicated such as, but not limited to, having a pacemaker or claustrophobia; diagnosis or signs of type 1 diabetes (e.g. history of positive islet antibodies); creatinine clearance \<60 ml/min at screening (cockcroft-gault formula).

Keywords: omega-3 carboxylic acid
comparison of brimonidine purite, dorzolamide, and brinzolamide as adjunctive therapy to prostaglandin analogs

Conditions: Primary Open Angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to compare the efficacy of brimonidine purite, dorzolamide, and brinzolamide in reducing intraocular pressure when added to prostaglandin analog therapy (bimatoprost, latanoprost, or travoprost) in patients with glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * diagnosis of primary open-angle glaucoma or ocular hypertension. * must be over 40 years of age. * intraocular pressure must be 18 mm hg or higher after 6 weeks of treatment (run-in) with a prostaglandin analog (bimatoprost, latanoprost, or travoprost). exclusion criteria: * history of angle closure or narrow angle. * previous intraocular surgery. * laser trabeculoplasty within 3 months prior to screening. * history of uveitis or intraocular inflammation. * use of medications other than the study medications that are known to affect iop (e.g., beta-blockers, steroids, or angiotensin ii blockers) within 3 months of study entry or during the study. * intolerance of or hypersensitivity to prostaglandin analogs, sulfonamides, alpha-agonists, or the preservative benzalkonium chloride. * women of childbearing age who are pregnant or not using contraception.

Keywords: glaucoma ocular hypertension adjunctive treatment prostaglandin prostaglandin analog brimonidine dorzolamide brinzolamide alpha agonist carbonic anhydrase inhibitor intraocular pressure
extubation failure prevention in high risk patients by high-flow conditioned oxygen therapy vs. standard oxygen therapy

Conditions: Respiratory Failure

Summary: failure of extubation after mechanical ventilation is a frequent and deleterious issue. main reasons for failure are hypoxemia, secretions retention, lung collapse and excessive work of breathing. most of this issues can be partly counterbalanced by a device named "high flow conditioned oxygen therapy (hfco)". then, our hypothesis is that hfco may reduce the incidence of respiratory failure after extubation in patients with high risk for failure.


Eligibility criteria:
inclusion criteria: * patients mechanically ventilated for \> 48 hours and at least one of the following: * \>65 years * cardiac failure as the primary indication of mechanical ventilation * chronic obstructive pulmonary disease * severity score (apache ii \>12 points) the extubation day * body mass index \>30 * inability to manage respiratory secretions * 1 failed spontaneous breathing trial * 1 comorbidity * 7 days under mechanical ventilation exclusion criteria: * \<18 years * tracheotomized patients * recent facial or cervical trauma/surgery * active gastro-intestinal bleeding * lack of cooperation * patients with any failed spontaneous breathing trial because of hypercapnia development.

Keywords: post-extubation respiratory failure endotracheal intubation mechanical ventilation
intratumoral and peritumoral habitat radiomics of mri predict pathologic complete response to neoadjuvant chemoimmunotherapy in oral squamous cell carcinoma

Conditions: Pathologic Complete Response

Summary: background：neoadjuvant chemoimmunotherapy (naci) shows promise in oral squamous cell carcinoma (oscc), but reliable noninvasive biomarkers for predicting pathologic complete response (pcr) remain scarce. radiomics integrating intratumoral and peritumoral heterogeneity across multi-sequence mri may offer novel insights into treatment response evaluation. methods: the data of 212 patients with oscc after naci were retrospectively collected and analyzed. among these patients, 56 (26.4%) achieved pcr after naci. intratumoral and peritumoral habitat imaging (hi) was achieved using the k-means clustering algorithm applied to t1-weighted imaging (t1wi), axial t2-weighted imaging with fat suppression (t2wi), and contrast-enhanced t1-weighted imaging with fat suppression (t1c). moreover, intratumoral and peritumoral hi models were constructed and compared using the receiver operating characteristic (roc) curve. five-fold cross-validation was performed to mitigate model overfitting.


Eligibility criteria:
inclusion criteria: * histopathologically confirmed oscc at the initial diagnosis; * no treatment received prior to the first mri examination; * receipt of naci; * underwent mri examination after naci; * underwent surgical intervention. exclusion criteria: * absence of clinical data and postoperative pathological results; * mri image artifacts significantly affecting image quality.

Keywords: oral squamous cell carcinoma radiomics intratumoral and peritumoral habitat imaging pathologic complete response
emotional awareness and self-regulation for depression in patients with hypertension (ease) study

Conditions: Hypertension

Summary: the purpose of this study is to adapt and then evaluate the feasibility, acceptability, and efficacy of a telephone-based intervention (uplift: using practice and learning to increase favorable thoughts) for individuals with elevated depressive symptoms and hypertension. uplift is a group-based intervention that is delivered over 8 weekly sessions for 1 hour/week by phone. aim 1 of this study is to adapt uplift using qualitative focus groups and individual interviews and to test the adapted uplift program in a single-arm design. aim 2 of this study is a randomized controlled trial (rct) that will compare the effects of the adapted uplift program to usual care (uc) and to test mediators and moderators of the effects of uplift.

once 16 participants are enrolled (to form 2 groups of 8 patients each), an independent study staff member will determine participants' group assignments. the randomization sequence will be created a priori by dr. keith goldfeld (biostatistician) by using a computer-generated list of random numbers with stratification by antidepressant medication use and baseline levels of depressive symptoms (phq scores \<10 and ≥10). uplift: eligible participants will complete 8 weekly group sessions by phone. the intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment. usual care: subjects randomized to uc will be advised to seek help from their primary care physician (pcp) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. all treatments received over the course of the study for the uc group and outside of the study (for the intervention group) will be assessed at each time point.

Eligibility criteria:
inclusion criteria: * diagnosis of hypertension based on the criteria in the icd-9/-10 * mild to moderate depressive symptoms (phq-9 ≥ 5) * english-speaking * if taking depression medications, medications must stable for the past 6 weeks (no change to type or dose) * willing to provide informed consent, be audio-recorded, and comply with all other aspects of protocol exclusion criteria: * moderate to severe depressive symptoms (phq-9 ≥ 15) * current substance abuse * current eating disorder * self-harm within the past 3 months * current obsessive-compulsive disorder * current anxiety disorder (e.g., ptsd, panic disorder) * active suicidal ideation * history of or current diagnosis of psychosis * significant cognitive impairment (mini mental state examination score ≤ 20) * history of previous training in mindfulness * history of more than 8 sessions of cognitive behavioral therapy * counseling more frequently than once per month

Keywords: hypertension coping relaxing
from uncomplicated alcoholism to korsakoff's syndrome

Conditions: Alcoholism; Alcohol Amnestic Disorder

Summary: this research project aims to identify factors that contribute to the heterogeneity observed in neuroradiological and neuropsychological signs of chronic alcoholism. the investigators overarching hypothesis is that the heterogeneity of alcoholic consequences on brain structure and metabolism, and cognition is mainly related to individual differences in pattern of alcohol use, gene pool, nutritional status and history of withdrawal symptoms.


Eligibility criteria:
inclusion criteria: * completed at least 8 years of education (primary school equivalent) * age-normal corrected hearing and visual acuity exclusion criteria: * documented loss of consciousness of over 30 minutes, documented compound skull fracture, or clear neurological sequelae of head trauma * history of medical or neurological illness or trauma potentially affecting the cns, e.g., stroke, multiple sclerosis, epilepsy, psychosurgery, insulin coma. * active tuberculosis or history of or any malignancy requiring chemotherapy * history of schizophrenia or bipolar disorder * metal implantation (e.g., pacemakers) or other factors that preclude mri scanning for subjects selected for the neuroimaging examination * meet dsm-iv criteria for current (past 3 months) other substance abuse * met dsm-iv criteria for other substance dependence * have used other substances more than 5 times in the past month

Keywords: magnetic resonance imaging positon emission tomography behavior
safety of amg 706 plus panitumumab plus gemcitabine-cisplatin in the treatment of patients with advanced cancer

Conditions: Lung Cancer; Pancreatic Cancer; Esophageal Cancer

Summary: the purpose of this study is to characterize the safety and tolerability of amg 706 plus panitumumab when administered with gemcitabine and cisplatin chemotherapy. this is a phase 1b clinical study.


Eligibility criteria:
for complete inclusion and exclusion, please refer to the investigator. inclusion criteria: * competent to comprehend, sign, and date an institutional review board (irb) approved informed consent form * subjects with advanced cancer in whom the gemcitabine and cisplatin chemotherapy regimen is clinically indicated * eastern cooperative oncology group (ecog) performance status of 0 or 1 * adequate hematological function * adequate renal function * adequate hepatic function * life expectancy of greater than or equal to 3 months as documented by the investigator exclusion criteria: * more than 1 prior chemotherapy regimen * history of venous thrombosis * myocardial infarction, cerebrovascular accident, transient ischemic attack, percutaneous transluminal coronary angioplasty/stent, or unstable angina within 1 year before study enrollment * history of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on screening chest computed tomograph (ct) scan * average systolic blood pressure of greater than 145 mm hg or average diastolic blood pressure of greater than 85 mm hg * radiotherapy within 28 days of study enrollment or within 14 days of study enrollment for peripheral lesions * prior amg 706, panitumumab, or another anti-egfr monoclonal antibody (mab) (e.g., cetuximab \[erbitux®\] or emd 72000) * systemic chemotherapy within 28 days before study enrollment * major surgery within 28 days or minor surgery within 14 days of study enrollment * central nervous system metastases (exception: subjects with treated asymptomatic central nervous system metastases, those who have been clinically stable in the judgment of the investigator and off steroids for at least 30 days before the study enrollment are eligible)

Keywords: advanced cancer amg 706 panitumumab gemcitabine-cisplatin
clinical course of korean crohn's disease cohort

Conditions: Crohn's Disease

Summary: in the past decade, the incidence and prevalence of cd (crohn's disease) has continued to increase in korea. previous studies have indicated that asian ibd (inflammatory bowel disease) patients differ from those of western patients with regard to the genetic susceptibility and some clinical features. however, the available published data from retrospective studies in korea were largely incomplete. the investigators aim of the study is a set-up of korean cohort for cd, and thereby to assess the clinical course of korean cd patients through a prospective multicenter long-term follow-up study. secondary aims of this study are as follows: (1) to evaluate the efficacy, tolerability, and predictors to response to anti-tnf therapy for cd, (2) to identify the risk factors for postoperative recurrence on the basis of information obtained at initial diagnosis, and (3) to evaluate genotype-phenotype correlation.

from 2009 to 2018, new cases of cd diagnosed will be recruited. participants for this study will be enrolled from 33 academic teaching hospitals or colorectal specialized hospitals across korea. medical records will be used to register demographic data, disease phenotype, the use of medication, flare-ups, surgery, hospitalizations, and mortality. whole blood will be collected to central biobank with extraction of dna ans seroum. the montreal classification of crohn's disease and the crohn's disease activity index (cdai) will be used to describe disease location, behavior and severity. f/u data will be analyzed using kaplan-meier analysis with log rank test and cox regression analysis. an electronic database will be established in use of processing data.

Eligibility criteria:
inclusion criteria: * patients over the age of 16 * informed consent * patients who had a definitive diagnosis of crohn's disease (documented by the standard clinical, radiographic, endoscopic, and histopathologic criteria) * be capable of understanding the study and replying to the questionnaires exclusion criteria: * any condition which, in the opinion of the investigator, places the patient at unacceptable risk if he/she were to participate in the study

Keywords: crohn's disease
intravenous administration of insulin and plasma exchange on triglyceride levels in early stage of hypertriglyceridemia-induced pancreatitis

Conditions: Pancreatitis, Acute; Hypertriglyceridemia

Summary: to investigate an economical and effective way to reduce the level of serum triglyceride in patients with hypertriglyceridemia-induced acute pancreatitis.


Eligibility criteria:
inclusion criteria: 1. adult aged 18 to 80 years old; 2. abdominal pain consistent with ap; 3. serum amylase and / or lipase activity is at least 3 times higher than the normal upper limit; 4. abdominal imaging consistent with ap imaging changes. 5. severe hyperlipidemia "fasting serum tg\> 1,000 mg/dl (11.2mmol/l)"; 6. except for other ap causes, such as cholelithiasis, alcohol, drugs and so on. exclusion criteria: 1. other etiologies other than hyperlipidemia leading to ap; 2. fasting serum tg less than 1,000 mg / dl (11.2mmol / l); 3. acute lipid-induced pancreatitis at the same time combined with other etiologies of acute pancreatitis. 4. the existence of plasma replacement contraindications: serious allergies to plasma, human serum albumin, heparin and others; the existence of mental disorders; unstable heart or cerebral infarction; intracranial hemorrhage or severe cerebral edema associated with hernia. 5. without informed consent, the patient refused to plasma replacement, and other circumstances may bring significant bias.

Keywords: hypertriglyceridemia-induced acute pancreatitis insulin triglyceride treatment
utility of gene test analysis for diagnosis, prognosis and treatment of patients with genetic arrhythmic heart disease: the arrhythmic gene-heart

Conditions: Genetic Disease; Cardiac Disease; Cardiac Arrhythmias; Genetic Disorder; Cardiology

Summary: the goal of this observational study is to enroll all patients evaluated at the specialized cardiogenetic center within the cardiology department of the university of ferrara, italy. the primary aim of the registry is to collect comprehensive clinical, genetic, and electrophysiological data from individuals with suspected or confirmed arrhythmogenic conditions. by systematically documenting patient demographics, family history, clinical presentations, diagnostic findings, and treatment outcomes, the registry seeks to enhance our understanding of the genetic basis and clinical implications of genetically driven arrhythmias and systemic syndromes. this registry will facilitate long-term follow-up of enrolled patients to assess the natural history of arrhythmogenic disorders and the effectiveness of various therapeutic interventions. additionally, it aims to identify potential risk factors associated with adverse outcomes, such as sudden cardiac death or major arrhythmic events.

cardiogenetics is essential in daily clinical practice, providing critical insights into the genetic basis of inherited cardiovascular conditions. this knowledge enables more accurate diagnoses, risk assessments, and personalized management strategies for patients. by understanding the genetic underpinnings of arrhythmias and other heart diseases, healthcare providers can identify at-risk individuals and their family members, facilitating early intervention and preventive measures. establishing an observational registry for these conditions is vital, as it systematically collects data on patient demographics, clinical presentations, genetic findings, and treatment outcomes. this comprehensive database enhances our understanding of the natural history and variability of genetic cardiovascular disorders while supporting research efforts aimed at developing improved diagnostic tools and therapeutic approaches. ultimately, such a registry can enhance patient care by informing clinical guidelines and fostering collaboration among clinicians, geneticists, and researchers in the field. therefore, the goal of this observational study is to gather extensive clinical, genetic, and electrophysiological data from individuals with suspected or confirmed arrhythmogenic conditions. by systematically documenting patient demographics, family history, clinical presentations, diagnostic findings, and treatment outcomes, the registry aims to deepen our understanding of the genetic basis and clinical implications of genetically driven arrhythmias and systemic syndromes.

Eligibility criteria:
inclusion criteria: * patients evaluated at the cardiogenetic center of the university of ferrara in ferrara, italy. * having a proven cardiogenetic disease exclusion criteria: * refuse to provide informed consents * patients not having a cardiogenic disease

Keywords: cardiogenetic